A Phase 3 interventional study of Placebo and paliperidone palmitate in Schizoaffective Disorder, sponsored by Janssen Scientific Affairs, LLC. Completed at 84 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-05.
Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing paliperidone in Psychotic Disorders — 1 open to participants now, 1 under way, none of them phase 3. paliperidone · Psychotic Disorders.
Among the 22 studies testing paliperidone in Psychotic Disorders, this one has the largest enrollment, is one of 2 that started in 2010, is one of 6 in phase 3, and was the 10th registered.
1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.
Browse Psychotic Disorders studies →1 of the 22 studies testing paliperidone in Psychotic Disorders is open now. Recruiting first, the newest first:
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 7 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2010.
This study's enrollment of 667 is above the median of 65 across 1,322 interventional studies indexed under Psychotic Disorders.
Median enrollment 189 across the 22 interventional studies. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
58 studies in Psychotic Disorders by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 57 finished, 12 (21%) have results posted.
Among the 58 studies in Psychotic Disorders by Johnson & Johnson, this one is the 4th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2010, is one of 24 in phase 3, and was the 49th registered.
Johnson & Johnson’s Psychotic Disorders studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing paliperidone in Psychotic Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 58 in Psychotic Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder. This study will also assess the safety and tolerability of paliperidone palmitate in patients with schizoaffective disorder.
Schizoaffective disorder is a chronic illness and generally requires life-long treatment. To date however, no medication has been evaluated in the maintenance treatment of schizoaffective disorder. This is a randomized (study drug assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of paliperidone palmitate, as monotherapy or as an adjunct to mood stabilizers or antidepressants, relative to placebo in delaying the time to relapse in patients with schizoaffective disorder. This study explores the use of paliperidone palmitate either as monotherapy or as an adjunct to mood stabilizers or antidepressants (MS/AD) because both treatment approaches are commonly used in the clinical management of schizoaffective disorder. Patients with acute symptoms of schizoaffective disorder will be enrolled. The study will consist of 4 periods: an up to 7 days screening/tolerability period, a 13-week open-label flexible dose lead-in period, a 12-week open-label fixed dose stabilization period, and a 15 months double-blind relapse prevention period. Patients without previous exposure to paliperidone ER (Invega), paliperidone palmitate (Invega Sustenna), risperidone, or RISPERDAL CONSTA will be given 4 to 6 days of paliperidone ER 6mg/day for tolerability testing. Patients can continue their current antipsychotic regimen through Day -1 (the day before the start of the study period). During the open-label periods, all patients will be treated with paliperidone palmitate. An initial loading dose of 234 mg (150 mg eq.) of paliperidone palmitate will be given by deltoid injection followed by 156 mg (100 mg eq.) deltoid injection on Day 8. Starting on Day 36, injections may be administered in either the deltoid muscle or the gluteal muscle. Doses at Days 36, 64 and 92 may be increased or decreased within the range of 78 mg (50 mg eq.) and 234 mg (150 mg. eq.) as clinically indicated. Dose will be fixed (at Day 92 dose) during the 12-week stabilization period. Patients who meet pre-determined stabilization criteria will be eligible to enter the double-blind relapse prevention period and will be randomly assigned to either receive paliperidone palmitate (at the Day 92 dose) or placebo treatment. Patients will have intramuscular (i.m.) study drug injection and efficay and saftety evaluations performed every 4 weeks throughout the study. Efficacy will be evaluated during the study using a relapse assessment, the Positive and Negative Symptom Scale (PANSS), the Clinical Global Impression of Severity for Schizoaffective Disorder (CGI-S-SCA), the Personal and Social Performance Scale (PSP), the Young Mania Rating Scale (YMRS), and the Hamilton Rating Scale for Depression (HAM-D). Safety will be assessed throughout the study by monitoring of adverse events, clinical laboratory tests, electrocardiograms (ECGs), vital sign measurements (temperature, pulse, and blood pressure), weight, and the monitoring of extrapyramidal symptoms using the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A). Suicidality will be assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). A 10 milliliter pharmacogenomic blood sample (sample for DNA research) will be collected from patients who give separate written informed consent for this part of the study. Participation in pharmacogenomic research is optional. Blood samples will be taken from patients being treated with lithium or valproate for the measurement of blood lithium or valproate levels. Approximately 52 mL (31 mL for patients who are not receiving lithium or valproate) of whole blood will be collected during the study. All patients will receive paliperidone palmitate 78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for the the first 25 weeks of the study (open-label periods). During the 15-month double-blind relapse prevention period, one half of the patients will be randomized to paliperidone palmitate treatment (50, 75, 100, or 150 mg eq. monthly i.m. injection) and the other half of the patients will be randomized to monthly placebo injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
Drug: paliperidone palmitate
Placebo monthly by i.m. injection for 15 months
Drug: Placebo
monthly by i.m. injection for 15 months
78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
Double-blind: Percentage of Participants Who Experienced Relapse
Relapse was defined as first occurrence of any 1 of following:psychiatric hospitalization due to worsening symptoms; any intervention employed to avert imminent hospitalization due to worsening symptoms or need for additional antipsychotic,antidepressants/mood stabilizing medication; deliberate self-injury,suicidal/homicidal ideation that is clinically significant as determined by investigator,or violent behavior resulting in clinically significant injury to another person or property damage; worsening of any 1 or more of 8 selected positive and negative syndrome scale(PANSS) items to a score of greater than or equal to (\>= 6) after randomization(if the score for the corresponding item was less than or equal to \[\<=\] 4 at randomization); worsening of certain other measures in specific ways at 2 consecutive visits. Relapse by subgroup of participants on monotherapy,adjunctive therapy to antidepressants/mood stabilizers,participants with psychotic symptoms/mood symptoms was examined.
Time frame: Day 1 up to Month 15 of double blind relapse prevention period
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 64 (Total Mixed Model Repeated Measures [MMRM] Analysis of Covariance [ANCOVA])
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.
Time frame: Baseline and Week 64 of double blind relapse prevention period
Open-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.
Time frame: Baseline and Endpoint (Week 13/LOCF) in Open-label (OL) Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.
Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. Number of participants in each specific category; good functioning (PSP total score \>70), variable functioning (PSP total score between 31 and 70), and poor functioning (PSP total score \<=30) were assessed.
Time frame: Baseline and Endpoint (Week 64/LOCF) in DB period
Open-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Double-blind: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period
Open-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.
Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Double-blind: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.
Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period
Open-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.
Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Double-blind: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.
Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period
Open-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".
Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Double-blind: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".
Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period
| Milestone | Paliperidone Palmitate | Placebo |
|---|---|---|
| Started | 667 | 0 |
| Completed | 432 | 0 |
| Not completed | 235 | 0 |
| Withdrew: Lost to follow-up | 32 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 69 | 0 |
| Withdrew: > 6 weeks between 2 study drug | 4 | 0 |
| Withdrew: Other | 14 | 0 |
| Withdrew: Subject failed stabilization criteria | 47 | 0 |
| Withdrew: Adverse event | 41 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 26 | 0 |
| Milestone | Paliperidone Palmitate | Placebo |
|---|---|---|
| Started | 432 | 0 |
| Completed | 334 | 0 |
| Not completed | 98 | 0 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 |
| Withdrew: Lack of efficacy | 5 | 0 |
| Withdrew: Withdrawal by subject | 29 | 0 |
| Withdrew: Subject failed stabilization criteria | 35 | 0 |
| Withdrew: Other | 8 | 0 |
| Milestone | Paliperidone Palmitate | Placebo |
|---|---|---|
| Started | 164 | 170 |
| Completed | 100 | 65 |
| Not completed | 64 | 105 |
| Withdrew: Other | 2 | 3 |
| Withdrew: Adverse event | 12 | 3 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 9 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 19 | 30 |
| Withdrew: Experienced relapse | 25 | 57 |
| Withdrew: > 6 weeks between 2 study drug | 1 | 3 |
Relapse was defined as first occurrence of any 1 of following:psychiatric hospitalization due to worsening symptoms; any intervention employed to avert imminent hospitalization due to worsening symptoms or need for additional antipsychotic,antidepressants/mood stabilizing medication; deliberate self-injury,suicidal/homicidal ideation that is clinically significant as determined by investigator,or violent behavior resulting in clinically significant injury to another person or property damage; worsening of any 1 or more of 8 selected positive and negative syndrome scale(PANSS) items to a score of greater than or equal to (\>= 6) after randomization(if the score for the corresponding item was less than or equal to \[\<=\] 4 at randomization); worsening of certain other measures in specific ways at 2 consecutive visits. Relapse by subgroup of participants on monotherapy,adjunctive therapy to antidepressants/mood stabilizers,participants with psychotic symptoms/mood symptoms was examined.
| percentage of participants | Paliperidone Palmitate | Placebo |
|---|---|---|
| All Participants (n=164, 170) | 15.2 (NA to NA) | 33.5 (NA to NA) |
| Monotherapy subset (n=78, 73) | 11.5 | 32.9 |
| Adjunct therapy subset (n=86, 97) | 18.6 | 34.0 |
| Psychotic Symptoms (n=164, 170) | 12.8 | 31.2 |
| Mood Symptoms;Any Mood Symptoms (n=164, 170) | 11.0 | 28.2 |
| Mood Symptoms;Manic (n=164, 170) | 3.0 | 9.4 |
| Mood Symptoms;Depressive (n=164, 170) | 4.9 | 13.5 |
| Mood Symptoms; Mixed (n=164, 170) | 3.0 | 5.3 |
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| Baseline (n=164, 170) | 72.8 ± 0.81 | 74.5 ± 0.81 |
| Change at Week 64 (n=98, 65) | 2.0 ± 0.92 | -1.3 ± 1.03 |
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.
| Units on a Scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| OL Lead-in Period:Baseline (n=667) | 51.4 ± 11.02 | — |
| OL Lead-in Period:Change at Endpoint (n=622) | 12.6 ± 13.71 | — |
| OL Stabilization Period:Change at Endpoint (n=622) | 13.8 ± 14.92 | — |
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.
| Units on a Scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| Double-blind: Baseline (n=164, 170) | 74.5 ± 0.81 | 72.8 ± 0.81 |
| Double-blind: Change at Endpoint (n=161,168) | 0.5 ± 1.15 | -4.1 ± 1.13 |
The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. Number of participants in each specific category; good functioning (PSP total score \>70), variable functioning (PSP total score between 31 and 70), and poor functioning (PSP total score \<=30) were assessed.
| participants | Paliperidone Palmitate | Placebo |
|---|---|---|
| Baseline: Poor (n=164, 170) | 0 | 0 |
| Baseline: Variable (n=164, 170) | 69 | 84 |
| Baseline: Good (n=164, 170) | 95 | 86 |
| Endpoint: Poor (n=161, 168) | 1 | 4 |
| Endpoint: Variable (n=161, 168) | 65 | 95 |
| Endpoint: Good (n=161, 168) | 95 | 69 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| OL Lead-in Period:Baseline (n=667) | 85.8 ± 12.76 | — |
| OL Lead-in Period:Change at Endpoint (n=653) | -21.8 ± 16.39 | — |
| OL Stabilization Period:Change at Endpoint (n=653) | -23.8 ± 18.30 | — |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| Double-blind: Baseline (n=164, 170) | 51.1 ± 9.50 | 51.8 ± 9.47 |
| Double-blind: Change at Endpoint (n=161, 168) | 0.5 ± 14.01 | 7.4 ± 18.53 |
The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| OL Lead-in Period:Baseline (n=667) | 20.4 ± 7.81 | — |
| OL Lead-in Period:Change at Endpoint (n=653) | -9.7 ± 8.53 | — |
| OL Stabilization Period:Change at Endpoint (n=653) | -9.9 ± 9.08 | — |
The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| Double-blind: Baseline (n=164, 170) | 5.7 ± 3.24 | 5.6 ± 3.32 |
| Double-blind: Change at Endpoint (n=161, 168) | 0.8 ± 5.40 | 3.4 ± 7.42 |
The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| OL Lead-in Period:Baseline (n=667) | 18.6 ± 9.48 | — |
| OL Lead-in Period:Change at Endpoint (n=653) | -9.9 ± 9.45 | — |
| OL Stabilization Period:Change at Endpoint (n=653) | -10.5 ± 10.14 | — |
The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| Double-blind: Baseline (n=164, 170) | 4.4 ± 3.46 | 4.4 ± 3.40 |
| Double-blind: Change at Endpoint (n=161,168) | -0.1 ± 5.47 | 3.2 ± 7.21 |
The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| OL Lead-in Period:Baseline (n=667) | 4.4 ± 0.58 | — |
| OL Lead-in Period:Change at Endpoint (n=652) | -1.3 ± 0.99 | — |
| OL Stabilization Period:Change at Endpoint (n=652) | -1.3 ± 1.07 | — |
The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".
| Units on a scale | Paliperidone Palmitate | Placebo |
|---|---|---|
| Double-blind: Baseline (n=164, 170) | 2.4 ± 0.68 | 2.5 ± 0.69 |
| Double-blind: Change at Endpoint (n=161,168) | 0.0 ± 1.02 | 0.4 ± 1.15 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label - Paliperidone Palmitate | — | 54/667 (8.1%) | 332/667 (49.8%) |
| Double Blind - Paliperidone Palmitate | — | 9/164 (5.5%) | 79/164 (48.2%) |
| Double Blind - Placebo | — | 16/170 (9.4%) | 62/170 (36.5%) |
| Event | Open Label - Paliperidone Palmitate | Double Blind - Paliperidone Palmitate | Double Blind - Placebo |
|---|---|---|---|
| Schizoaffective DisorderPsychiatric disorders | 16/667 | 1/164 | 7/170 |
| Suicidal IdeationPsychiatric disorders | 15/667 | 0/164 | 2/170 |
| DepressionPsychiatric disorders | 1/667 | 2/164 | 0/170 |
| Psychotic DisorderPsychiatric disorders | 4/667 | 2/164 | 2/170 |
| Cardiac Failure CongestiveCardiac disorders | 0/667 | 1/164 | 0/170 |
| Congestive CardiomyopathyCardiac disorders | 0/667 | 1/164 | 0/170 |
| Coronary Artery DiseaseCardiac disorders | 0/667 | 1/164 | 0/170 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 0/667 | 1/164 | 0/170 |
| Chest PainGeneral disorders | 0/667 | 1/164 | 0/170 |
| BronchitisInfections and infestations | 0/667 | 1/164 | 0/170 |
| Event | Open Label - Paliperidone Palmitate | Double Blind - Paliperidone Palmitate | Double Blind - Placebo |
|---|---|---|---|
| AkathisiaNervous system disorders | 74/667 | 5/164 | 3/170 |
| Injection Site PainGeneral disorders | 71/667 | 1/164 | 2/170 |
| InsomniaPsychiatric disorders | 67/667 | 8/164 | 12/170 |
| Weight IncreasedInvestigations | 57/667 | 14/164 | 8/170 |
| ParkinsonismNervous system disorders | 43/667 | 3/164 | 3/170 |
| NasopharyngitisInfections and infestations | 9/667 | 9/164 | 6/170 |
| HeadacheNervous system disorders | 36/667 | 9/164 | 6/170 |
| HyperprolactinaemiaEndocrine disorders | 9/667 | 7/164 | 2/170 |
| Upper Respiratory Tract InfectionInfections and infestations | 14/667 | 7/164 | 4/170 |
| PyrexiaGeneral disorders | 8/667 | 6/164 | 2/170 |
Open-label (OL) intent-to-treat (ITT) analysis set included all participants who received at least 1 injection of open-label study drug.
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 39.5 ± 10.70 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 310 |
| Male | 357 |
The record gives a start of Sep 2010, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 3 months after primary completion. A results delay was requested in Jun 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Scientific Affairs, LLC →